NCT06161246 is a Phase 4 clinical trial of Vibrating Beauty Bar in Injection Site Discomfort, sponsored by Galderma R&D.

Who is sponsoring NCT06161246?

NCT06161246 is sponsored by Galderma R&D.

What drugs are being tested in NCT06161246?

Interventions in NCT06161246: Vibrating Beauty Bar.

What condition does NCT06161246 study?

NCT06161246 studies Injection Site Discomfort.

Is NCT06161246 still recruiting?

NCT06161246 is currently completed. Last updated 22 March 2024.

Last reviewed 2024-03-22 · How we verify

NCT06161246

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction

Completed Phase 4 Last updated 22 March 2024

What this trial tests

Phase 4 trial testing Vibrating Beauty Bar in Injection Site Discomfort in 60 participants. Completed in 15 February 2024.

Timeline

23 October 2023

Primary endpoint
15 February 2024

15 February 2024

Quick facts

Lead sponsor	Galderma R&D
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	23 October 2023
Primary completion	15 February 2024
Estimated completion	15 February 2024
Sites	1 location across United States

Drugs / interventions tested

Vibrating Beauty Bar

Conditions studied

Injection Site Discomfort — all drugs for Injection Site Discomfort →

Sponsor

Galderma R&D — full company profile →

Who can join

Adults 18 to 64, any sex, with Injection Site Discomfort. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single-center, randomized, split-face, controlled study to assess the effect of comfort intervention on pain during treatment injection compared against non-comfort intervention.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Neuromodulator Co-Administration With a Vibration Device: Patient Comfort Study.
Dayan S, Gandhi N, Carvajal C, Nguyen TQ, et al · · 2025 · PMID 40599709 · DOI 10.1093/asjof/ojaf026

Verify or expand the search:

Other Galderma R&D trials

Trials by the same sponsor.

NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
NCT07344584 — A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles · NA · not yet recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07398989 — A Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin · Phase 4 · completed
NCT06988618 — Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06161246 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Galderma R&D
Last refreshed: 22 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06161246.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing